US equities |
MU $989.04 ▲+0.00% SNDK $1,487.33 ▲+0.00% SKHY $162.23 ▲+0.00% NVDA $226.32 ▲+0.00% INTC $101.35 ▲+0.00% AMD $594.24 ▲+0.00% META $742.96 ▲+0.00% TSLA $378.03 ▲+0.00%
FinancialContent

Fulgent Genetics, Inc. - Common Stock (NQ:FLGT)

21.47 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Fulgent Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Fulgent Reports Second Quarter 2026 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Fulgent Presents Updated FID-007 Data at ASCO 2026
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Fulgent Reports First Quarter 2026 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
FULGENT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
From Kirby McInerney LLP
Via Business Wire
News headline image
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
FLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
From Kirby McInerney LLP
Via Business Wire
News headline image
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Fulgent to Participate in Upcoming Conferences
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Fulgent Reports Third Quarter 2025 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Fulgent Reports Second Quarter 2025 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM
From Fulgent Genetics, Inc.
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating GoHealth, Semler, Adtran, and Fulgent and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >